Muscular dystrophies

Modalis Partners with SOLVE FSHD to Develop CRISPR...
CMN Briefs

Jun. 9, 2025

Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...

Muscular dystrophies

Facioscapulohumeral Muscular Dystrophy, (NCT06907875)
Sponsors:
Epicrispr Biotechnologies
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Duchenne Muscular Dystrophy, DMD, (NCT06594094)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Duchenne Muscular Dystrophy, DMD, (NCT05514249)
Sponsors:
Cure Rare Disease, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
Limb Girdle Muscular Dystrophy, LGMD, (NCT05588401)
Sponsors:
Simone Spuler, MD
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine